The Group's principal activity is development and sale of pharmaceuticals. The products include OX 40 for treating migraine, OX 19 for treating urinary incontinence, OX 17 for treating gastroesophageal reflux disease, Sublinox for treating temporary insomnia, Rapinyl for treating breakthrough cancer pain, Diabact UBT and HeliProbe Systems for conducting breath tests. The Group operates in United States, European Union and Southeast Asia.
Alacra Alerts:
Receive alerts on the latest reports on Orexo AB
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
